Ruxolitinib (Jakavi®)

Assessment Status Assessment Process Complete
HTA ID -
Drug Ruxolitinib
Brand Jakavi®
Indication For the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
Assessment Process
Rapid review commissioned 01/08/2012
Rapid review completed 10/08/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 20/12/2012
NCPE assessment completed 09/07/2013
NCPE assessment outcome Reimbursement not Recommended

The NCPE do not consider ruxolitinib to be a cost effective treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations July 2015.